{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:33:12Z","timestamp":1786361592747,"version":"build-2736575974"},"reference-count":103,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016380","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:04:46Z","timestamp":1786359886000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor agonist-based regimens compared with metformin-based regimens for preventing cardiovascular disease in adults with type 2 diabetes mellitus"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1658-6574","authenticated-orcid":false,"given":"Sana","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Food and Nutrition; University of Delhi; New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P","family":"McCollin","sequence":"additional","affiliation":[{"name":"Pharmacy Enterprise; Cambridge Health Alliance; Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-3351","authenticated-orcid":false,"given":"Arturo","family":"Mart\u00ed-Carvajal","sequence":"additional","affiliation":[{"name":"C\u00e1tedra Rectoral de Medicina Basada en la Evidencia; Universidad de Carabobo; Valencia Venezuela"},{"name":"Faculty of Medicine; Universidad Francisco de Vitoria; Madrid Spain"},{"name":"Doctoral Program of Social Science (Health and Society); Universidad de Carabobo; Valencia Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Akus","sequence":"additional","affiliation":[{"name":"Pharmacy Enterprise; Cambridge Health Alliance; Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Baron","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; Cambridge Health Alliance, Harvard Medical School; Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Abdul Razzaq","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery; Tufts Medical Center; Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-3315","authenticated-orcid":false,"given":"Paige","family":"Scudder","sequence":"additional","affiliation":[{"name":"Hirsh Health Sciences Library; Tufts University; Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J","family":"Honigsberg","sequence":"additional","affiliation":[{"name":"Department of Medicine; Dartmouth Health; Lebanon New Hampshire USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifuddin","family":"Nasir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; University of Pittsburgh Medical Center (UPMC) Mercy Hospital; Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangning","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Medicine; Cambridge Health Alliance; Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6149-1067","authenticated-orcid":false,"given":"Shayesteh","family":"Jahanfar","sequence":"additional","affiliation":[{"name":"Department of Public Health and Community Medicine; Tufts University School of Medicine; Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"10365","key":"10.1002\/14651858.CD016380-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/s0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"issue":"03","key":"10.1002\/14651858.CD016380-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1055\/s-2002-23199","article-title":"Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes","volume":"34","author":"Lugari","year":"2002","journal-title":"Hormone and Metabolic Research"},{"issue":"3","key":"10.1002\/14651858.CD016380-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Vilsb\u00f8ll","year":"2001","journal-title":"Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD016380-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3109\/00365529609009147","article-title":"Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day","volume":"31","author":"Orskov","year":"1996","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD016380-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1677\/joe.0.1380159","article-title":"Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns","volume":"138","author":"Elliott","year":"1993","journal-title":"Journal of Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD016380-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiological Reviews"},{"issue":"3","key":"10.1002\/14651858.CD016380-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajcnut.2024.01.007","article-title":"Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions - a narrative review","volume":"119","author":"Huber","year":"2024","journal-title":"American Journal of Clinical Nutrition"},{"issue":"23","key":"10.1002\/14651858.CD016380-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/nejmoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovascular Diabetology"},{"issue":"2","key":"10.1002\/14651858.CD016380-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD016380-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.2337\/dc20-0886","article-title":"Contrasting associations between diabetes and cardiovascular mortality rates in low-, middle-, and high-income countries: cohort study data from 143,567 individuals in 21 countries in the PURE study","volume":"43","author":"Anjana","year":"2020","journal-title":"Diabetes Care"},{"issue":"9733","key":"10.1002\/14651858.CD016380-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Gao","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD016380-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Sarwar","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016380-BIB0015|cit15","unstructured":"International Diabetes Federation IDF diabetes atlas, 11th ed diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/ 2025"},{"key":"10.1002\/14651858.CD016380-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"851941","DOI":"10.3389\/fendo.2022.851941","article-title":"Endothelial dysfunction and diabetic cardiomyopathy","volume":"13","author":"Wang","year":"2022","journal-title":"Frontiers in Endocrinology"},{"issue":"0","key":"10.1002\/14651858.CD016380-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"s380","DOI":"10.1007\/s00592-003-0124-9","article-title":"Hyperglycaemia and its relation to cardiovascular morbidity and mortality: has it been resolved?","volume":"40","author":"Yosefy","year":"2003","journal-title":"Acta Diabetologica"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40001-024-02241-4","article-title":"Comparative efficacy of GLP-1 RAs\/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Zhang","year":"2025","journal-title":"European Journal of Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovascular Diabetology"},{"issue":"4","key":"10.1002\/14651858.CD016380-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD016380-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD016380-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/dom.12805","article-title":"Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"19","author":"Singh","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD016380-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD016380-BIB0024|cit24","unstructured":"Byetta\u00ae (exenatide) injection, prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021773s9s11s18s22s25lbl.pdf 2009"},{"key":"10.1002\/14651858.CD016380-BIB0025|cit25","unstructured":"Trulicity (dulaglutide) injection for subcutaneous use; prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125469s061s062lbl.pdf 2020"},{"issue":"8","key":"10.1002\/14651858.CD016380-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1463-1326.2012.01560.x","article-title":"GLP-1 based therapies: differential effects on fasting and postprandial glucose","volume":"14","author":"Fineman","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD016380-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s12325-017-0491-1","article-title":"The role of the pharmacist in managing type 2 diabetes with glucagon-like peptide-1 receptor agonists as add-on therapy","volume":"34","author":"Meece","year":"2017","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD016380-BIB0028|cit28","unstructured":"Ozempic (semaglutide) injection, for subcutaneous use; prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209637s020s021lbl.pdf 2020"},{"key":"10.1002\/14651858.CD016380-BIB0029|cit29","unstructured":"Sanofi-Aventis US Adlyxin (lixisenatide), prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/208471s010lbl.pdf 2016"},{"issue":"4","key":"10.1002\/14651858.CD016380-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD016380-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2174\/1871529x14666140505125300","article-title":"Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states","volume":"14","author":"Farr","year":"2014","journal-title":"Cardiovascular & Hematological Disorders-Drug Targets"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1185\/03007995.2015.1103214","article-title":"The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide","volume":"32","author":"Guo","year":"2015","journal-title":"Current Medical Research and Opinion"},{"issue":"10193","key":"10.1002\/14651858.CD016380-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1002\/14651858.CD016380-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/nejmoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"10.1002\/14651858.CD016380-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1161\/circulationaha.118.034516","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke","volume":"138","author":"Verma","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD016380-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/dom.13541","article-title":"Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"21","author":"Liakos","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2337\/db07-0827","article-title":"Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes","volume":"57","author":"Basu","year":"2008","journal-title":"Diabetes"},{"issue":"12","key":"10.1002\/14651858.CD016380-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","article-title":"Mechanism by which metformin reduces glucose production in type 2 diabetes","volume":"49","author":"Hundal","year":"2000","journal-title":"Diabetes"},{"issue":"8","key":"10.1002\/14651858.CD016380-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1055\/s-2006-949522","article-title":"Metformin increases blood flow and forearm glucose uptake in a group of non-obese type 2 diabetes patients","volume":"38","author":"Magalh\u00e3es","year":"2006","journal-title":"Hormone and Metabolic Research"},{"issue":"9","key":"10.1002\/14651858.CD016380-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1507\/endocrj.ej12-0068","article-title":"Effect of metformin on hepatic glucose production in Japanese patients with type 2 diabetes mellitus","volume":"59","author":"Takahara","year":"2012","journal-title":"Endocrine Journal"},{"issue":"2","key":"10.1002\/14651858.CD016380-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ando.2013.03.006","article-title":"Revisiting the mechanisms of metformin action in the liver","volume":"74","author":"Viollet","year":"2013","journal-title":"Annales d'Endocrinologie"},{"issue":"3","key":"10.1002\/14651858.CD016380-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/dom.12826","article-title":"Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes","volume":"19","author":"Preiss","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD016380-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.metabol.2008.11.009","article-title":"Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin","volume":"58","author":"Svendsen","year":"2009","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2337\/dc16-1324","article-title":"Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut","volume":"40","author":"la Cuesta-Zuluaga","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD016380-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3389\/fphys.2018.00775","article-title":"Understanding the representative gut microbiota dysbiosis in metformin-treated type 2 diabetes patients using genome-scale metabolic modeling","volume":"9","author":"Rosario","year":"2018","journal-title":"Frontiers in Physiology"},{"issue":"3","key":"10.1002\/14651858.CD016380-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"issue":"7","key":"10.1002\/14651858.CD016380-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.molmet.2017.05.002","article-title":"Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state","volume":"6","author":"Schommers","year":"2017","journal-title":"Molecular Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD016380-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2337\/dc12-0719","article-title":"Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease","volume":"36","author":"Hong","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD016380-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","article-title":"Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus","volume":"169","author":"Kooy","year":"2009","journal-title":"Archives of Internal Medicine"},{"issue":"9131","key":"10.1002\/14651858.CD016380-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD016380-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1002\/dmrr.3173","article-title":"Mechanisms of action of metformin with special reference to cardiovascular protection","volume":"35","author":"Zilov","year":"2019","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"issue":"4","key":"10.1002\/14651858.CD016380-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2337\/db06-0918","article-title":"Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program","volume":"56","author":"Lachin","year":"2007","journal-title":"Diabetes"},{"issue":"6","key":"10.1002\/14651858.CD016380-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"800","DOI":"10.2337\/dc16-2271","article-title":"Early glycemic control and magnitude of hba1c reduction predict cardiovascular events and mortality: population-based cohort study of 24,752 metformin initiators","volume":"40","author":"Svensson","year":"2017","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1002\/14651858.CD016380-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD016380-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-025-01623-w","article-title":"GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation","volume":"17","author":"Movahednasab","year":"2025","journal-title":"Diabetology & Metabolic Syndrome"},{"issue":"3","key":"10.1002\/14651858.CD016380-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2337\/dc24-1533","article-title":"Comparative efficacy of glucagon-like peptide 1 receptor agonists for cardiovascular outcomes in asian versus white populations: systematic review and meta-analysis of randomized trials of populations with or without type 2 diabetes and\/or overweight or obesity","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12933-022-01489-6","article-title":"Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6","volume":"21","author":"Husain","year":"2022","journal-title":"Cardiovascular Diabetology"},{"issue":"12","key":"10.1002\/14651858.CD016380-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/s2213-8587(21)00240-0","article-title":"Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis","volume":"9","author":"Global Health & Population Project on Access to Care for Cardiometabolic Diseases","year":"2021","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD016380-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/hsr2.2004","article-title":"Diabetes mellitus, the fastest growing global public health concern: early detection should be focused","volume":"7","author":"Hossain","year":"2024","journal-title":"Health Science Reports"},{"issue":"8","key":"10.1002\/14651858.CD016380-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/dci23-0042","article-title":"Lessons from insulin: policy prescriptions for affordable diabetes and obesity medications","volume":"47","author":"Nagel","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD016380-BIB0063|cit63","volume-title":"StatPearls [Internet]","author":"Latif","year":"2025"},{"key":"10.1002\/14651858.CD016380-BIB0064|cit64","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0065|cit65","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews (MECIR). Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD016380-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD016380-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD016380-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"12036","DOI":"10.1002\/cesm.12036","article-title":"Development of the InSynQ checklist: a tool for planning and reporting the synthesis questions in systematic reviews of interventions","volume":"1","author":"Cumpston","year":"2023","journal-title":"Cochrane Evidence Synthesis and Methods"},{"key":"10.1002\/14651858.CD016380-BIB0069|cit69","volume-title":"Cochrane Database of Systematic Reviews: Editorial policies","year":"2026"},{"key":"10.1002\/14651858.CD016380-BIB0070|cit70","unstructured":"Drugs@FDA: FDA-Approved Drugs. VICTOZA\u00ae (liraglutide) injection, for subcutaneous use. Revised July 2023 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022341s039lbl.pdf"},{"key":"10.1002\/14651858.CD016380-BIB0071|cit71","unstructured":"Drugs@FDA: FDA-Approved Drugs. MOUNJARO\u00ae (tirzepatide) Injection, for subcutaneous use. Revised November 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215866s010s015s022lbl.pdf"},{"key":"10.1002\/14651858.CD016380-BIB0072|cit72","unstructured":"Drugs@FDA: FDA-Approved Drugs. BYETTA\u00ae (exenatide) injection, for subcutaneous use. Revised November 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/021773s049lbl.pdf"},{"key":"10.1002\/14651858.CD016380-BIB0073|cit73","unstructured":"Drugs@FDA: FDA-Approved Drugs. OZEMPIC (Semaglutide) injection, for subcutaneous use. Revised November 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf"},{"key":"10.1002\/14651858.CD016380-BIB0074|cit74","unstructured":"Drugs@FDA: FDA-Approved Drugs. TRULICITY (dulaglutide) injection, for subcutaneous use. Revised November 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125469s061s062lbl.pdf"},{"issue":"S3","key":"10.1002\/14651858.CD016380-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/dom.15729","article-title":"Clinical efficacy and cost-effectiveness of metformin in different patient populations: a narrative review of real-world evidence","volume":"26","author":"Solini","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD016380-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"e1001204","DOI":"10.1371\/journal.pmed.1001204","article-title":"Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"9","author":"Boussageon","year":"2012","journal-title":"PLOS Medicine"},{"issue":"9","key":"10.1002\/14651858.CD016380-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD016380-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"3-4","key":"10.1002\/14651858.CD016380-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/rds.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Review of Diabetic Studies"},{"key":"10.1002\/14651858.CD016380-BIB0080|cit80","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies (chapter last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0081|cit81","unstructured":"Cumpston M Lasserson T Flemyng E Page MJ Chapter III: Reporting the review (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0082|cit82","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0083|cit83","unstructured":"Covidence Veritas Health Innovation 2015"},{"key":"10.1002\/14651858.CD016380-BIB0084|cit84","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2026"},{"key":"10.1002\/14651858.CD016380-BIB0085|cit85","unstructured":"Boutron I Page MJ Higgins JP Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0086|cit86","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD016380-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/nejme048225","article-title":"Clinical trial registration: a statement from the international committee of medical journal editors","volume":"351","author":"De Angelis","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016380-BIB0089|cit89","unstructured":"Food and Drug Administration Amendments Act of 2007 https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/food-and-drug-administration-amendments-act-fdaaa-2007 2007"},{"key":"10.1002\/14651858.CD016380-BIB0090|cit90","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"25334905","DOI":"10.1101\/2025.09.03.25334905","article-title":"INSPECT-SR: a tool for assessing trustworthiness of randomised controlled trials","volume":"2025.09.03","author":"Wilkinson","year":"2025","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD016380-BIB0092|cit92","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0093|cit93","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (chapter last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"issue":"10","key":"10.1002\/14651858.CD016380-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/s0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis","volume":"54","author":"Sterne","year":"2001","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016380-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"e076754","DOI":"10.1136\/bmj-2023-076754","article-title":"ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis","volume":"383","author":"Page","year":"2023","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016380-BIB0096|cit96","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0097|cit97","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0098|cit98","unstructured":"Stata StataCorp 2026"},{"key":"10.1002\/14651858.CD016380-BIB0099|cit99","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0100|cit100","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD016380-BIB0101|cit101","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2026"},{"key":"10.1002\/14651858.CD016380-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016380-BIB0103|cit103","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:04:50Z","timestamp":1786359890000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016380"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":103,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016380","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]}}}